Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In Niger, epidemic meningococcal meningitis is primarily caused by Neisseria meningitidis (Nm) serogroup A. However, since 2002, Nm serogroup W135 has been considered to be a major threat that has not yet been realized, and an unprecedented incidence of Nm serogroup X (NmX) meningitis was observed in 2006. METHODS: Meningitis surveillance in Niger is performed on the basis of reporting of clinically suspected cases. Cerebrospinal fluid specimens are sent to the reference laboratory in Niamey, Niger. Culture, latex agglutination, and polymerase chain reaction are used whenever appropriate. Since 2004, after the addition of a polymerase chain reaction-based nonculture assay that was developed to genogroup isolates of NmX, polymerase chain reaction testing allows for the identification of Nm serogroup A, Nm serogroup B, Nm serogroup C, NmX, Nm serogroup Y, and Nm serogroup W135. RESULTS: From January to June 2006, a total of 4185 cases of meningitis were reported, and 2905 cerebrospinal fluid specimens were laboratory tested. NmX meningitis represented 51% of 1139 confirmed cases of meningococcal meningitis, but in southwestern Niger, it represented 90%. In the agglomeration of Niamey, the reported cumulative incidence of meningitis was 73 cases per 100,000 population and the cumulative incidence of confirmed NmX meningitis was 27.5 cases per 100,000 population (74.6 cases per 100,000 population in children aged 5-9 years). NmX isolates had the same phenotype (X : NT : P1.5), and all belonged to the same sequence type (ST-181) as the NmX isolates that were circulating in Niamey in the 1990s. Nm serogroup W135 represented only 2.1% of identified meningococci. CONCLUSIONS: This is, to our knowledge, the first report of such a high incidence of NmX meningitis, although an unusually high incidence of NmX meningitis was also observed in the 1990s in Niamey. The increasing incidence of NmX meningitis is worrisome, because no vaccine has been developed against this serogroup. Countries in the African meningitis belt must prepare to face this potential new challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A high incidence of serogroup X disease was recently reported for Niger, representing 51% of 1,139 confirmed cases of meningococcal meningitis in 2006 (36).”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maiden, M. C. J., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Urwin, R., Zhang, Q., Zhou, J., Zurth, K., Caugant, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3140 · Cited by 3,833 · cited 1×
“A relevant selection of Nm isolates that had been collected during the meningitis epidemic season were sent to the World Health Organization’s Collaborating Centre for Reference and Research on Meningococci (Le Pharo, Marseilles, France) for serogroup confirmation, serotyping, and further determination, including mult…”
MethodBulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
mlstdbNet – distributed multi-locus sequence typing (MLST) databases
Jolley, K. A., Chan, M.-S., & Maiden, M. C. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-86 · Cited by 501 · cited 1×
“This publication made use of the Neisseria Multi Locus Sequence Typing website [26] developed by Keith Jolley and Man-Suen Chan and sited at the University of Oxford [29].”
MethodPCR for capsular typing of Haemophilus influenzae
Falla, T. J., Crook, D. W., Brophy, L. N., Maskell, D., Kroll, J. S., & Moxon, E. R. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.10.2382-2386.1994 · Cited by 413
Meningococcal meningitis in Africa
Greenwood, B. (1999) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(99)90106-2 · Cited by 358
Cerebrospinal meningitis in Africa.
Lapeyssonnie, L. (1963) · Europe PMC (PubMed Central) · Cited by 321
Taha, M.-K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.855-857.2000 · Cited by 260 · cited 2×
“For genogrouping of Nm-positive specimens, a second PCR is performed to amplify the siaD gene for Nm serotypes B, C, Y, and W135, and the open reading frame 2 of the mynB gene for NmA [16].”
MethodSelf-citationEpidemiology of bacterial meningitis in Niamey, Niger, 1981-96.
Campagne, G., Schuchat, A., Djibo, S., Ousseini, A., Cissé, L., & Chippaux, J. (1999) · Europe PMC (PubMed Central) · Cited by 182
Self-citationGarcía, P., García, J., García, E., & López, R. (1986) · Gene · doi:10.1016/0378-1119(86)90215-5 · Cited by 168
Chatelet, I. P. D., Traore, Y., Gessner, B. D., Antignac, A., Naccro, B., Njanpop-Lafourcade, B.-M., Ouedraogo, M. S., Tiendrebeogo, S. R., Varon, E., & Taha, M. K. (2005) · Clinical Infectious Diseases · doi:10.1086/426436 · Cited by 158 · cited 6×
“In 2002, the first epidemic ever identified in Africa as being caused by Nm serogroup W135 occurred in Burkina Faso [9] [10], and the risk of a rapid spread of the epidemic within the meningitis belt was considered to be high.”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 10
- Koumare B, Bougoudogo F, Cisse M, Doumbia T, Keita MM. Bacte- riological aspects of purulent meningitis in Bamako district: a propos of 1541 bacterial strains collected from 1979 to 1991 [in French]. Bull Soc Pathol Exot 1993; 86:136-40.
- 1993, Bulletin de la Soci t de pathologie exotique (1990), 86, 136
- Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a se- rogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002; 185:618-26.
- Parent du Chatelet I, Traore Y, Gessner BD, et al. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain re- action testing. Clin Infect Dis 2005; 40:17-25.
- World Health Organization. Meningococcal disease, serogroup W135, Burkina Faso: preliminary report, 2002. Wkly Epidemiol Rec 2002; 77: 152-5.
- World Health Organization (WHO). Enhanced surveillance of epi- demic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 2005; 80:313-20.
- 2002, Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 77, 152
- 2005, Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 80, 313
- Multi Disease Surveillance Centre (MDSC). Epidemiological situation of week 22 to 26, 2006. MDSC Meningitis Weekly Bulletin. Ouaga- dougou: World Health Organization-Regional Office for Africa, 2006.
- Traore Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006; 43:817-22.
Cited by
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-09 · Cited by 930
“A high incidence of serogroup X disease was recently reported for Niger, representing 51% of 1,139 confirmed cases of meningococcal meningitis in 2006 (36).”
BackgroundGlobal epidemiology of meningococcal disease
Harrison, L. H., Trotter, C. L., & Ramsay, M. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.063 · Cited by 755
Neisseria meningitidis: Biology, Microbiology, and Epidemiology
Rouphael, N. G., & Stephens, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-346-2_1 · Cited by 425
Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 404
Meningococcal carriage and disease—Population biology and evolution
Caugant, D. A., & Maiden, M. C. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.061 · Cited by 381
Global epidemiology of invasive meningococcal disease
Jafri, R. Z., Ali, A., Messonnier, N. E., Tevi-Benissan, C., Durrheim, D., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M., Sow, S., et al. (2013) · Population Health Metrics · doi:10.1186/1478-7954-11-17 · Cited by 372
“7 [17]”
Vesikari, T., Esposito, S., Prymula, R., Ypma, E., Kohl, I., Toneatto, D., Dull, P., & Kimura, A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61961-8 · Cited by 279
Santolaya, M. E., O'Ryan, M. L., Valenzuela, M. T., Prado, V., Vergara, R., Muñoz, A., Toneatto, D., Graña, G., Wang, H., Clemens, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61713-3 · Cited by 260
Trotter, C. L., Lingani, C., Fernandez, K., Cooper, L. V., Bita, A., Tevi-Benissan, C., Ronveaux, O., Préziosi, M.-P., & Stuart, J. M. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30301-8 · Cited by 242
Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Kristiansen, P. A., Diomandé, F., Ba, A. K., Sanou, I., Ouédraogo, A., Ouédraogo, R., Sangaré, L., Kandolo, D., Aké, F., Saga, I. M., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis892 · Cited by 212
Stephens, D. S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.070 · Cited by 198
Neisseria meningitidis: pathogenesis and immunity
Pizza, M., & Rappuoli, R. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2014.11.006 · Cited by 179
“Twelve different meningococcal serogroups have been defined based on the capsular polysaccharides of which five: A, B, C, W135, and Y are responsible for the majority of the disease, and with serogroup X more recently identified as cause of sepsis and meningitis in Africa [3].”
BackgroundMeningococcal carriage in the African meningitis belt
Trotter, C. L., & Greenwood, B. M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70288-8 · Cited by 174
“Most African epidemics have been caused by meningococci belonging to serogroup A (Greenwood 1999) but outbreaks caused by meningococci belonging to serogroup C, W or X meningococci have been reported (Broome et al. 1983; Decosas & Koama 2002; Boisier et al. 2007; Halperin et al. 2012).”
Meningococcal disease: changes in epidemiology and prevention
Stephens, D. S., Chang, Q., & Tzeng (2012) · Clinical Epidemiology · doi:10.2147/clep.s28410 · Cited by 167
Potential targets for next generation antimicrobial glycoconjugate vaccines
Micoli, F., Costantino, P., & Adamo, R. (2018) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuy011 · Cited by 165
“In Asia, a significant proportion of enteric fever is caused by S. Paratyphi A, while NTS, mainly S. Typhimurium and S. Enteritidis, is major cause of bloodstream infection in sub-Saharan Africa (MacLennan, Martin and Micoli 2014).”
BackgroundInfluentialEpidemiological Profile of Meningococcal Disease in the United States
Harrison, L. H. (2010) · Clinical Infectious Diseases · doi:10.1086/648963 · Cited by 150
Caugant, D. A. (2008) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2008.04.002 · Cited by 145
The epidemiology of meningococcal disease and the impact of vaccines
Khatami, A., & Pollard, A. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.3 · Cited by 142
Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013
Lingani, C., Bergeron-Caron, C., Stuart, J. M., Fernandez, K., Djingarey, M. H., Ronveaux, O., Schnitzler, J. C., & Perea, W. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ597 · Cited by 136
“An outbreak of NmX was seen in Niger in 2006 [17], and continues to cause a small proportion of cases, while an outbreak of NmC was recorded in northern Nigeria in 2013 and 2014 [18].”
BackgroundEmergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso
Delrieu, I., Yaro, S., Tamekloe, T. A., Njanpop‐Lafourcade, B., Tall, H., Jaillard, P., Ouedraogo, M. S., Badziklou, K., Sanou, O., Drabo, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019513 · Cited by 135
“seasonal cumulative incidences per 100,000 were 28 (95%-CI, 24– 31) in Niamey/Niger [7] and 33 (95%-CI, 26–42) in Kozah district/ Togo.”
BackgroundResultInfluentialA hypothetical explanatory model for meningococcal meningitis in the African meningitis belt
Mueller, J. E., & Gessner, B. D. (2009) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2009.08.013 · Cited by 128
Development of a group A meningococcal conjugate vaccine,MenAfriVacTM
Frasch, C. E., Préziosi, M., & LaForce, F. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19619 · Cited by 127
“Use of multiple doses of a group A meningococcal PS vaccine in the African Expanded Programme on Immunization (EPI) was a strategy that was discussed at length but not chosen because of the logistic demands that such a strategy imposes; rather, international groups including WHO recommended that a new Men A conjugate…”
BackgroundInfluentialEmergence of serogroup X meningococcal disease in Africa: Need for a vaccine
Xie, O., Pollard, A. J., Mueller, J. E., & Norheim, G. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.036 · Cited by 126
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
Bai, X., Findlow, J., & Borrow, R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.585965 · Cited by 106
“Of these, six serogroups A, B, C, Y, W135 [1] and X [2] are responsible for the majority of meningococcal disease globally.”
BackgroundHong, E., Giuliani, M. M., Deghmane, A., Comanducci, M., Brunelli, B., Dull, P. M., Pizza, M., & Taha, M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.022 · Cited by 115
Self-citationSoeters, H. M., Diallo, A. O., Bicaba, B. W., Kadadé, G., Dembélé, A. Y., Acyl, M. A., Nikiema, C. S., Sadji, A. Y., Poy, A., Lingani, C., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz358 · Cited by 107
Østergaard, L. J., Lebacq, E., POOLMAN, J. T., Maechler, G., & Boutriau, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.075 · Cited by 105
Airborne dust and high temperatures are risk factors for invasive bacterial disease
Jusot, J., Neill, D. R., Waters, E. M., Bangert, M., Collins, M., Bricio-Moreno, L., Katiellou, G. L., Moussa, M. M., Dearing, E., Everett, D., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.062 · Cited by 105
Mustapha, M. M., Marsh, J. W., & Harrison, L. H. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.014 · Cited by 103
Lucidarme, J., Tan, L., Exley, R. M., Findlow, J., Borrow, R., & Tang, C. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00055-11 · Cited by 94
Rohokale, R., & Guo, Z. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00559 · Cited by 95
Funk, A. L., Uadiale, K., Kamau, C., Caugant, D. A., Ango, U., & Greig, J. E. (2014) · PLoS Currents · doi:10.1371/currents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518 · Cited by 94
The next decade of vaccines: societal and scientific challenges
Moxon, E. R., & Siegrist, C. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60407-8 · Cited by 94
Sidikou, F., Zaneidou, M., Alkassoum, I., Schwartz, S., Issaka, B. B., Obama, R., Lingani, C., Tate, A. H., Aké, F. H., Sakandé, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30253-5 · Cited by 88
Self-citationAgier, L., Martiny, N., Thiongane, O., Mueller, J. E., Paireau, J., Watkins, E., Irving, T., Koutangni, T., & Broutin, H. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.032 · Cited by 83
Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen
Seib, K. L., Scarselli, M., Comanducci, M., Toneatto, D., & Masignani, V. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1016915 · Cited by 70
“Pajon R, Fergus AM, Granoff DM. Mutant native outer membrane vesicles combined with a Serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa.”
BackgroundKnuf, M., Kieninger‐Baum, D., Habermehl, P., Muttonen, P., Maurer, H., Vink, P., POOLMAN, J. T., & Boutriau, D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.064 · Cited by 81
Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges
Mustapha, M. M., & Harrison, L. H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412020 · Cited by 77
“Niger experienced a larger NmX epidemic in 2006 with 581 confirmed cases and incidence of 28 cases per 100,000 population in Niamey.6 Epidemiologic and clinical characteristics, such as seasonality, age and sex distribution and case fatality rates were similar between NmX and NmA.78 A significant increase in NmX cases…”
ResultBeernink, P. T., Caugant, D. A., Welsch, J. A., Koeberling, O., & Granoff, D. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/597806 · Cited by 76
“Recent outbreaks of meningococcal disease caused by capsular group X strains also were reported in Ghana [8, 39], Niger [7], and Kenya and Uganda [40].”
BackgroundCollard, J.-M., Issaka, B., Zaneidou, M., Hugonnet, S., Nicolas, P., Taha, M.-K., Greenwood, B., & Jusot, J.-F. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-576 · Cited by 63
“However, serogroup C was responsible for epidemics in Nigeria in the 1970s [2] and in Upper Volta (now Burkina Faso) in the 1980s [3], serogroup W sequence type (ST)-11 caused severe epidemics in Burkina Faso in 2002 and 2003 [4,5], and serogroup X caused an outbreak in Niger in 2006 [6].”
BackgroundSelf-citationEmergence and control of epidemic meningococcal meningitis in sub-Saharan Africa
Mohammed, I., Iliyasu, G., & Habib, A. G. (2017) · Pathogens and Global Health · doi:10.1080/20477724.2016.1274068 · Cited by 72
Fernandez, K., Lingani, C., Aderinola, O. M., Kadadé, G., Bicaba, B. W., Edea, Z. A., Glele-Kakai, C., Sarkodie, B., Tamekloe, A., Ngomba, A. V., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz355 · Cited by 72
“NmX was detected in only 1 outbreak, but it has caused major outbreaks in the past [19, 20], and was detected increasingly in 2017 and 2018 [21, 22].”
BackgroundSystematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci
Dellicour, S., & Greenwood, B. M. (2007) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2007.01929.x · Cited by 69
“…belonging to serogroup A (Greenwood 1999), although epidemics have recently been described that were caused by meningococci belonging to serogroup W135 (Decosas & Koama 2002; Forgor et al. 2005; Traoré et al. 2006) or serogroup X (Gagneux et al. 2002; Djibo et al. 2003; Boisier et al. 2007).”
Micoli, F., Romano, M. R., Tontini, M., Cappelletti, E., Gavini, M., Proietti, D., Rondini, S., Swennen, E., Santini, L., Filippini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314476110 · Cited by 68
“In 2010, a MenA conjugate vaccine (MenAfriVac) was rolled out in a mass vaccination program in Burkina Faso, Mali, and Niger (9).”
BackgroundInfluentialKoeberling, O., Ispasanie, E., Hauser, J., Rossi, O., Pluschke, G., Caugant, D. A., Saul, A. J., & MacLennan, C. A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.068 · Cited by 67
Caugant, D. A., Kristiansen, P. A., Wang, X., Mayer, L. W., Taha, M., Ouédraogo, R., Kandolo, D., Bougoudogo, F., Sow, S. O., & Bonte, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046019 · Cited by 67
“During the 7-year period analysed here, Niger experienced a serogroup X outbreak in 2006 [3] and the responsible epidemic strain was ST-181 (Table 1).”
BackgroundSelf-citationSáfadi, M. A. P., Ayala, S. E. G., Jäkel, A., Wieffer, H., Moreno, C. S., & Vyse, A. (2012) · Epidemiology and Infection · doi:10.1017/s0950268812001689 · Cited by 67
“and X accounting for virtually all cases of invasive disease [3, 4].”
BackgroundKeiser, P. B., Gibbs, B. T., Coster, T. S., Moran, E. E., Stoddard, M. B., Labrie, J. E., Schmiel, D. H., Pinto, V. B., Chen, P., & Zollinger, W. D. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.048 · Cited by 66
“[4] Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, et al.”
BackgroundInvasive meningococcal disease and travel
Memish, Z. A., Goubeaud, A., Bröker, M., Malerczyk, C., & Shibl, A. M. (2010) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2010.09.008 · Cited by 66
Relative stability of meningococcal serogroup A and X polysaccharides
Berti, F., Romano, M. R., Micoli, F., Pinto, V., Cappelletti, E., Gavini, M., Proietti, D., Pluschke, G., MacLennan, C. A., & Costantino, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.021 · Cited by 64
Fagnocchi, L., Biolchi, A., Ferlicca, F., Boccadifuoco, G., Brunelli, B., Brier, S., Norais, N., Chiarot, E., Bensi, G., Kroll, J. S., et al. (2012) · Infection and Immunity · doi:10.1128/iai.01085-12 · Cited by 63
Meningococcal Disease: The Organism, Clinical Presentation, and Worldwide Epidemiology
Al‐Tawfiq, J. A., Clark, T. A., & Memish, Z. A. (2010) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2010.00448.x · Cited by 60
Mutonga, D., Pimentel, G., Muindi, J. M., Nzioka, C., Mutiso, J., Klena, J. D., Morcos, M., Ogaro, T., Materu, S. F., Tetteh, C., et al. (2009) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.619 · Cited by 60
“< 5 12 (17) 18% (0–41) 54,090 22 05–14 29 (41) 22% (6–38) 105,364 28 15−24 12 (17) 8% (0–23) 83,614 14 25−44 8 (11) 14% (0–40) 83,185 10 3 45 9 (13) 22% (0–49) 44,147 20”
Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing
Kugelberg, E., Gollan, B., & Tang, C. M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.059 · Cited by 60
Corpora in translation studies
Baker, M. (2003) · Routledge eBooks · doi:10.4324/9780203359792-23 · Cited by 59
Brynildsrud, O. B., Eldholm, V., Bohlin, J., Uadiale, K., Obaro, S., & Caugant, D. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802298115 · Cited by 58
Pajón, R., Fergus, A. M., Koeberling, O., Caugant, D. A., & Granoff, D. M. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001302 · Cited by 57
“this region [11–14].”
Memish, Z. A., Dbaibo, G. S., Montellano, M., Verghese, V. P., Jain, H., Dubey, A. P., Bianco, V., der Wielen, M. V., GATCHALIAN, S. R., & Miller, J. M. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31820e6e02 · Cited by 56
Stamboulián, D., Lopardo, G. D., López, P., Cortes-Barbosa, C., Valencia, A., Bedell, L., Karsten, A., & Dull, P. M. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.03.017 · Cited by 54
“An unprecedented incidence of serogroup X was reported in Niger, Africa in 2006.(12) Serogroups B and C are predominant in most regions, including Europe and Latin America.”
BackgroundMueller, J. E., Yaro, S., Madec, Y., Somda, P., Idohou, R. S., Njanpop‐Lafourcade, B., Drabo, A., Tarnagda, Z., Lassana, S., Traoré, Y., et al. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2008.02165.x · Cited by 54
“Serogroups W135 (NmW135) and X (NmX) also cause occasional epidemics in the region (Boisier et al. 2007; World Health Organization 2008).”
BackgroundCase-fatality ratio of bacterial meningitis in the African meningitis belt: We can do better
Boisier, P., Maïnassara, H. B., Sidikou, F., Djibo, S., Kairo, K. K., & Chanteau, S. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.036 · Cited by 54
Self-citationWatkins, E., & Maiden, M. C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045349 · Cited by 53
“In addition, there is no vaccine available against serogroup X, which has recently caused disease outbreaks in Africa [5–6].”
BackgroundDupin, N., Lécuyer, H., Carlotti, A., Poyart, C., Coureuil, M., Chanal, J., Schmitt, A., Vacher‐Lavenu, M., Taha, M., Nassif, X., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis120 · Cited by 51
“5% of reported invasive meningococcal infections in France [9, 10].”
BackgroundInfluentialSelf-citationGasparini, R., Comanducci, M., Amicizia, D., Ansaldi, F., Canepa, P., Orsi, A., Icardi, G., Rizzitelli, E., Angelis, G. D., Bambini, S., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03584-13 · Cited by 51
“meningococci have also revealed an epidemic potential (21).”
BackgroundTsang, R. S. W. (2021) · Microorganisms · doi:10.3390/microorganisms9020449 · Cited by 50
“However, a serogroup X meningococcus (MenX) epidemic was reported from southwest Niger in 2004-2006 [82], and subsequently MenX outbreaks had occurred in Burkina Faso, Niger, Togo, and Uganda [83].”
BackgroundMeningococcal serogroup Y emergence in Europe: Update 2011
Bröker, M., Jacobsson, S., Kuusi, M., Pace, D., Simões, M. J., Skoczyńska, A., Taha, M., Toropainen, M., & Tzanakaki, G. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21794 · Cited by 49
“Although disease caused by serogroup X has been documented in Africa, it is not a common cause of IMD in other parts of the world.(6) Worldwide, over 90% of IMD is caused by serogroups A, B, C, Y and W-135.”
BackgroundSelf-citationDbaibo, G. S., Khinkarly, R. W., & Hedari, C. (2014) · Infection and Drug Resistance · doi:10.2147/idr.s36243 · Cited by 49
“It was licensed in India in 2009 and launched in Burkina Faso, Mali, and Niger.”
Deghmane, A., Taha, S., & Taha, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1971289 · Cited by 48
Self-citationPaireau, J., Girond, F., Collard, J., Maïnassara, H. B., & Jusot, J. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001577 · Cited by 48
“A subsequent analysis will differentiate serogroups of meningococci as their spatio-temporal patterns may significantly vary [32,33].”
BackgroundVaccines for low-income countries
MacLennan, C. A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.004 · Cited by 47
Fiebig, T., Berti, F., Freiberger, F., Pinto, V., Claus, H., Romano, M. R., Proietti, D., Brogioni, B., Stummeyer, K., Berger, M., et al. (2013) · Glycobiology · doi:10.1093/glycob/cwt102 · Cited by 47
“NmX has historically been associated with only sporadic or small clusters of disease, but outbreaks of NmX occurred in Niger (Boisier et al. 2007), Uganda, Kenya (Mutonga et al.”
BackgroundSerogroup X in Meningococcal Disease, Western Kenya
Materu, S. F., Cox, H. S., Isaakidis, P., Bienvenu, B., Ogaro, T., & Caugant, D. A. (2007) · Emerging infectious diseases · doi:10.3201/eid1306.070042 · Cited by 47
“In 2006, however, 51% of 1,139 confi rmed cases of meningococcal meningitis in Niger were found to be caused by serogroup X (5).”
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Gamougam, K., Daugla, D. M., Toralta, J., Ngadoua, C., Fermon, F., Page, A., Djingarey, M. H., Caugant, D. A., Manigart, O., Trotter, C. L., et al. (2014) · Emerging infectious diseases · doi:10.3201/eid2101.140256 · Cited by 45
Greenwood, B. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.035 · Cited by 45
“The majority of African epidemics have been caused by meningococci belonging to serogroup A but substantial outbreaks caused by meningococci belonging to serogroup C, W135 or X have also occurred [5-7].”
BackgroundVaccination strategies for the prevention of meningococcal disease
Vuocolo, S. C., Balmer, P., Gruber, W. C., Jansen, K. U., Anderson, A. S., Perez, J. L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451287 · Cited by 45
Morelli, L., Cancogni, D., Tontini, M., Nilo, A., Filippini, S., Costantino, P., Romano, M. R., Berti, F., Adamo, R., & Lay, L. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.247 · Cited by 44
Croxtall, J. D., & Dhillon, S. (2012) · Drugs · doi:10.2165/11209580-000000000-00000 · Cited by 43
“[73] Although the clinical significance of this decline in hSBA-MenA antibody titres is unknown,[25] waning of antibody titres could result in increased susceptibility to meningococcal serogroup A disease, which may have implications for regions with high prevalence of this serogroup, such as in parts of Africa.”
BackgroundInfluentialQuadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
Pace, D. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.18 · Cited by 43
Dbaibo, G. S., El-Ayoubi, N. K., Ghanem, S., Hajar, F., Bianco, V., Miller, J. M., & Mesaros, N. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0065-0 · Cited by 42
“Serogroups A and W-135 are also responsible for major epidemics in Africa [1, 5], while serogroup X emerged more recently as a cause of local outbreaks in Africa [6–9].”
BackgroundBai, X., & Borrow, R. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.116 · Cited by 42
Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
Kriz, P., Wieffer, H., Holl, K., Rosenlund, M., Budhia, S., & Vyse, A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.117 · Cited by 41
Oldrini, D., Fiebig, T., Romano, M. R., Proietti, D., Berger, M., Tontini, M., Ricco, R. D., Santini, L., Morelli, L., Lay, L., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b01057 · Cited by 41
Tzeng, Y., & Stephens, D. S. (2021) · Microorganisms · doi:10.3390/microorganisms9030519 · Cited by 41
“MenX is the latest group to cause large localized outbreaks in Kenya [36,37], Niger [34,35], Ghana [33], Mali, and Burkina Faso [38].”
BackgroundMeningococcal carriage in the A frican meningitis belt
The MenAfriCar consortium (2013) · Tropical Medicine & International Health · doi:10.1111/tmi.12125 · Cited by 40
“Most African epidemics have been caused by meningococci belonging to serogroup A (Greenwood 1999) but outbreaks caused by meningococci belonging to serogroup C, W or X meningococci have been reported (Broome et al. 1983; Decosas & Koama 2002; Boisier et al. 2007; Halperin et al. 2012).”
Dbaibo, G. S., Macalalad, N. G., Reyes, M. R. A.-D. L., Dimaano, E. M., Bianco, V., Baine, Y., & Miller, J. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20211 · Cited by 39
Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies
Sáfadi, M. A. P., & McIntosh, E. D. G. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.159 · Cited by 39
Future challenges in the elimination of bacterial meningitis
Bottomley, M. J., Serruto, D., Sáfadi, M. A. P., & Klugman, K. P. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.099 · Cited by 39
“While it is not anticipated that he MenA vaccine will result in serogroup replacement in Africa, the vidence for recent epidemics of Men W-135 and X in the meninitis belt highlight the additional need for a multivalent vaccine overing serogroups A, W-135 and X [57–59].”
BackgroundNeisseria meningitidisSerogroup X in Sub-Saharan Africa
Agnememel, A., Hong, E., Giorgini, D., Núñez-Samudio, V., Deghmane, A., & Taha, M. (2016) · Emerging infectious diseases · doi:10.3201/eid2204.150653 · Cited by 38
“In 2006, high incidence of serogroup X was first reported in Niamey, Niger (4), and thereafter in other countries, reinforcing the need for an effective vaccine against serogroup X (5).”
BackgroundSelf-citationGlobal review of meningococcal disease. A shifting etiology
Leimkugel, J., Racloz, V., da Silva, L. J., & Pluschke, G. (2009) · doi:10.5897/jbr.9000024 · Cited by 38
Shirley, M., & Dhillon, S. (2015) · BioDrugs · doi:10.1007/s40259-015-0139-0 · Cited by 37
“Five of these (A, B, C, W, and Y) are responsible for the vast majority of IMD cases in most parts of the world [2, 6, 7], with a sixth serogroup (X) having emerged as a substantial cause of meningococcal disease in the meningitis belt of Africa [7, 8].”
Meningococcal disease in travelers: update on vaccine options
Cramer, J. P., & Wilder‐Smith, A. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283574c06 · Cited by 37
“This is particularly worrisome as it is feared that the gap induced by effective group A vaccinations may be filled by alternative serogroups [13,24,25].”
BackgroundHarale, K. R., Rout, J. K., Chhikara, M. K., Gill, D. S., & Misra, A. K. (2017) · Organic Chemistry Frontiers · doi:10.1039/c7qo00468k · Cited by 37
Coldiron, M. E., Assao, B., Page, A., Hitchings, M. D. T., Alcoba, G., Ciglenečki, I., Langendorf, C., Mambula, C., Adehossi, E. O., Sidikou, F., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002593 · Cited by 36
Devenish, S. R. A., Huisman, F. H. A., Parker, E. J., Hadfield, A. T., & Gerrard, J. A. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.003 · Cited by 36
Mueller, J. E., Yaro, S., Njanpop‐Lafourcade, B., Drabo, A., Idohou, R. S., Kroman, S. S., Sanou, O., Diagbouga, S. P., Traoré, Y., Sangaré, L., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir623 · Cited by 36
“The incidence pattern of bacterial meningitis in the African meningitis belt is characterized by ubiquitous hyperendemicity of meningococcal and pneumococcal meningitis during the dry season.”
BackgroundTrotter, C. L., Yaro, S., Njanpop‐Lafourcade, B., Drabo, A., Kroman, S. S., Idohou, R. S., Sanou, O., Bowen, L., Findlow, H., Diagbouga, S. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055486 · Cited by 35
“W135 [4] and X[5;6] have also been implicated.”
BackgroundMeningococcal serogroup Y emergence in Europe: High importance in some European regions in 2012
Bröker, M., Bukovski, S., Culic, D., Jacobsson, S., Koliou, M., Kuusi, M., Simões, M. J., Skoczyńska, A., Toropainen, M., Taha, M., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28206 · Cited by 35
Self-citationShirley, M., & Taha, M. (2018) · Drugs · doi:10.1007/s40265-018-0869-7 · Cited by 36
“Five of these (A, B, C, W and Y) are responsible for the vast majority of IMD cases in most parts of the world, with a sixth serogroup (X) having emerged as a substantial cause of meningococcal disease in the meningitis belt of Africa [2, 7, 8].”
BackgroundSelf-citationThe Risk of Meningococcal Disease in Travelers and Current Recommendations for Prevention
Steffen, R. J. (2010) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2010.00449.x · Cited by 34
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
Miller, J. M., Mesaros, N. E., der Wielen, M. V., & Baine, Y. (2011) · Advances in Preventive Medicine · doi:10.4061/2011/846756 · Cited by 34
“SAGE-Hindawi Access to Research Advances in Preventive Medicine Volume 2011, Article ID 846756, 17 pages doi:10.4061/2011/846756”
MethodInfluential
Metadata
- Authors
- Boisier, P., Nicolas, P., Djibo, S., Taha, M.-K., Jeanne, I., Mainassara, H. B., Tenebray, B., Kairo, K. K., Giorgini, D., & Chanteau, S.
- Affiliations
- Centre de Recherche Médicale et Sanitaire (NE)
- World Health Organization (CH)
- Institut Pasteur (FR)
- Ministère de la Santé Publique (NE)
- Corresponding author
- Boisier, P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 44
- Issue
- 5
- Pages
- 657-663
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2159099211
- Cited by
- 237
- References
- 26
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 12 · 2016: 15 · 2015: 14 · 2014: 21 · 2013: 23 · 2012: 34
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- World Health Organization
- Wellcome Trust
- University of Oxford
- European Commission
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- meningococcal meningitis, serogroup W135, epidemic meningitis, meningitis incidence, Niger, Niamey, serogroup replacement, children aged 5-9 years
- MeSH terms
- Disease Outbreaks, Humans, Meningitis, Meningococcal, Neisseria meningitidis, Niger, Serotyping, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.